SNCA and Parkinson disease: Therefore, in order to combat α-synuclein pathology and protect dopaminergic neurons in PD, treatment for the restoration of microglial lysosomal function, induction of mitophagy, or modification of their metabolic processes to create an anti-inflammatory, pro-clearance phenotype is essential (Alrouji et al. 2023; Chen et al. 2023) [Table 1].